|Bid||3.4700 x 4000|
|Ask||3.5000 x 2200|
|Day's Range||3.3200 - 3.8500|
|52 Week Range||1.1300 - 11.5100|
|Beta (3Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Biotech stocks rebounded in last week after declining modestly in the previous week. Some of the drugs that cleared the FDA hurdle this week include Ardelyx Inc (NASDAQ: ARDX )'s constipation drug Ibsrela; ...
In addition to a $260 million payout, the drug dispute settlement returns worldwide development and commercialization rights to Houston-area firm.
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 10) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...
Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista. Under the terms of the settlement, Sanofi will pay $208 million upfront and the remainder within twelve months to Lexicon, which was eligible to receive up to $1.4 billion in milestone payments under the partnership. The four-year partnership was terminated by Sanofi in July after the results of three late-stage studies of Zynquista, which is being developed as an add-on to insulin for diabetic patients.
THE WOODLANDS, Texas, Sept. 10, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for ZynquistaTM (sotagliflozin) will be presented at.
Lexicon Pharmaceuticals, Inc. (LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of ZynquistaTM (sotagliflozin) and the settlement of its related disputes with Sanofi, each effective September 9, 2019. In connection with the termination, Lexicon will regain all rights to Zynquista and assume full responsibility for the worldwide development and commercialization of Zynquista in both type 1 and type 2 diabetes.
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX): Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on...
THE WOODLANDS, Texas, Aug. 30, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and.
President and CEO of Lexicon Pharmaceuticals Inc (30-Year Financial, Insider Trades) Lonnel Coats (insider trades) bought 40,000 shares of LXRX on 08/19/2019 at an average price of $1.35 a share. Continue reading...
THE WOODLANDS, Texas, Aug. 09, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and.
Changes in Clinical Biomarkers Suggestive of Favorable Effects on Kidney Function in Patients with Type 1 Diabetes Results Recently Published in Diabetes Care THE WOODLANDS,.
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
Lexicon (LXRX) delivered earnings and revenue surprises of -144.44% and -60.73%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
THE WOODLANDS, Texas, July 31, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended.
Lexicon Pharmaceuticals, Inc. (LXRX), announced today that it has changed the date of its previously announced earnings release, conference call and webcast and will now release financial results for the second quarter of 2019 on Wednesday, July 31, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss the financial results and to provide a business update.
Shares of Lexicon Pharmaceuticals Inc. lost more than half their value (down 53.4%) toward a record low in active premarket trading Monday, after the drug maker said Sanofi wanted to end the alliance around its diabetes treatment Zynquista. The stock was on track to open 38% below its Jan. 29, 2019 record low close of $4.36, with trading volume of 583,000 shares already more than the full-day average of 349,800 shares. Lexicon said it considers Sanofi's notice to be invalid and "in breach of contract." Sanofi's decision to terminate the alliance late Friday came as Lexicon provided preliminary data from a phase 3 trial of Zynquista; Lexicon said it has not yet received the underlying data and expects to conduct its own review and validation of the statistical analysis. Analyst Stephen Wiley at Stifel Nicolaus downgraded Lexicon's stock to hold from buy and cut his price target to $4 from $10, saying Sanofi's notice creates more uncertainty for Lexicon's story, which "already lacked meaningful visibility." The stock has lost 14% year to date through Friday, while the S&P 500 has gained 21%.
Sanofi said the termination of the partnership comes after the results of three late-stage studies of the oral drug, Zynquista, which is being jointly developed by the two companies. In a separate statement, Lexicon said it had not yet received the underlying data from the studies and that it expects to conduct its own review. "While we are disappointed in the position taken by Sanofi, we are confident in the strength of the data we have seen thus far in the type 2 diabetes program," Lexicon Chief Executive Officer Lonnel Coats said.
French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop a drug for use with insulin in patients with type 1 and type 2 diabetes. Shares of Lexicon fell nearly 40% in extended trading. Sanofi said the termination of the partnership comes after the results of three late-stage studies of the oral drug, Zynquista, which is being jointly developed by the two companies.
Lexicon Pharmaceuticals, Inc. (LXRX), received preliminary topline results from Sanofi for three Phase 3 trials of Zynquista™ (sotagliflozin) in adults living with type 2 diabetes from the InSynchrony clinical program. In SOTA-MET, Zynquista 400 mg demonstrated a statistically significant reduction in blood sugar control (A1C) compared to placebo at 26 weeks in patients on metformin. In SOTA-CKD3, Zynquista 400 mg showed a statistically significant reduction in A1C in the entire population of patients with moderate (stage 3) chronic kidney disease (CKD) and in the subpopulation of patients with a glomerular filtration rate of 45-